AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00890097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-8309B Ophthalmic Solution
Study NCT00890097 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AL-8309B Vehicle
Description: Inactive ingredients used as placebo comparator
Study NCT02608346 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood sampling
Description: Patients will have a blood draw at each visit to the hospital,~* with a maximum of 1 blood draw every 3 months, in absence of any abnormal clinical/radiological exam~* with a maximum of 1 blood draw every week, in case of abnormal clinical/radiological exam that requires further investigation
Study NCT03948620 — intervention group
Intervention type: DRUG
Intervention: Macrolides
Description: Macrolide antibiotics, including erythromycin, clarithromycin and azithromycin. Prescriptions of macrolides will be identified using a drug code list based on the British National Formulary (chapter 5.1.5) and the date of the first prescription was used as the index date of exposure.
Study NCT03948620 — intervention group
Intervention type: DRUG
Intervention: Penicillins
Description: The comparison group consists of children whose mother were prescribed penicillins during pregnancy. Prescriptions of penicillins will be identified using a drug code list based on the British National Formulary (chapter 5.1.1) and the date of the first prescription will be used as the index date of exposure.
Study NCT02852005 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA/HIV62B vaccine
Description: 1×10\^8 TCID50 dose to be administered as a 1 mL intramuscular (IM) injection in the deltoid
Study NCT04661020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD19 CAR-T cells
Description: Each subject receive CD19 CAR T-cells by intravenous infusion
Study NCT02330809 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Daily extra water intake
Description: Amount of extra daily water intake to consume
Study NCT02852005 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AIDSVAX B/E vaccine
Description: 600 mcg/mL dose to be administered as a 1 mL IM injection in the deltoid
Study NCT02852005 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sodium Chloride for Injection USP, 0.9% to be administered as a 1 mL IM injection in the deltoid
Study NCT02239484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Study NCT02239484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin
Study NCT02239484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil + Tamsulosin
Study NCT01947673 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness Meditation
Study NCT01947673 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Health Education
Study NCT02796144 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lorcaserin
Description: Max dose of 10 mg BID
Study NCT03702374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combined antioxidant therapy
Description: It consists in a tablet with lutein (10 mg), astaxanthin (4 mg), Zeaxanthin (1mg), vitamin C (L-ascorbic acid 180mg), vitamin E (DL-alpha tocopherol 30mg), zinc (zinc oxide 20mg), copper (copper sulfate 1mg), taken once a day for 12 months
Study NCT03702374 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: It consists in a capsule with 100mg of magnesium oxide.
Study NCT01406054 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: neuromuscular exercises
Description: neuromuscular exercises delivered as a pre-practice and pre-game warm-up including dynamic stretching, strengthening, and plyometrics.
Study NCT03949114 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Evaluation
Description: Evaluate a weak debilitating phenotype screening on the patients before surgery;
Study NCT03949114 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Evaluation
Description: Evaluate a weak debilitating phenotype screening on the patients before surgery;
Study NCT03949114 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: nursing care
Description: Traditional post-operative nursing care
Study NCT03949114 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: rehabilitation
Description: 1. Postoperative vital signs were stabilized for 2 hours and then assisted to turn over; 2 to 3 hours to change position, awake without swallowing dysfunction, to fluid diet; 6 hours later, raise the bed 15 to 30 °, eat a half-flow diet.~2. On the first day after surgery, raise the bed 45 °, row and position training; catheter clamping training; assessment of pain, preventive analgesia. Early rehabilitation training was performed for 60 minutes each time for 5 consecutive days.
Study NCT03898609 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: 3 weeks
Study NCT03272165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI1341
Description: Participants will receive IV infusion of MEDI1341 doses as stated in the arms' description.
Study NCT03272165 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive IV infusion of placebo matched to MEDI1341.
Study NCT03763266 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1 day low residue diet
Description: Patients are interviewed and instructed by a nurse prior the colonoscopy. They receive oral and written dietary information. In case of morbidity associated with bad preparation they are given bisacodyl the night before the colonoscopy.
Study NCT02796144 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Max dose of 1,000 mg BID
Study NCT02796144 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebos will be administered for each drug.
Study NCT01704872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ch14.18/CHO
Study NCT02004990 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single cleansing procedure of 10% Povidone Iodine
Description: Single cleansing procedure of 10% Povidone Iodine prior to an in-office 5% Sodium Fluoride varnish application
Study NCT03237845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimegepant
Description: 75 mg tablet QD
Study NCT03237845 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet to match rimegepant dose QD
Study NCT01749735 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: Continuous mild transcranial direct current stimulation will be used while the participant plays video games using the Armeo Spring Robot to support the affected arm. Intervention: 40 minute training sessions, 5 days a week for 2 weeks.
Study NCT03763266 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 3 day low residue diet
Description: Patients are interviewed and instructed by a nurse prior the colonoscopy. They receive oral and written dietary information. In case of morbidity associated with bad preparation they are given bisacodyl the night before the colonoscopy.
Study NCT03607786 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Retrograde Inferior Vena Caval Perfusion
Description: Retrograde Inferior Vena Caval Perfusion is achieved by tethering the inferior vena cava with a band around the cannula and by clamping the distal end of the inferior vena cava drainage tube, which allowed a pump to drive oxygenated blood into the inferior vena cava. Pump pressure is maintained at 20-30 mmHg, and blood flow is maintained at 8-12 mL/min/kg. The aim of RIVP is to maintain the lower body perfusion during circulation arrest, and reduce the ischemia-associated vital organ injury.
Study NCT03607786 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Select antegrade cerebral perfusion
Description: Antegrade cerebral perfusion is achieved using a 12 F cannula inserted into the brachiocephalic artery or right axillary artery. The antegrade perfusion flow rate is maintained at 6-12 mL/min/kg
Study NCT04090359 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dual Mobility Implant
Description: Patients in this intervention will receive a dual mobility implant
Study NCT04090359 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional, single-bearing implant
Description: Patients in this intervention will receive a conventional, single-bearing implant
Study NCT01065766 — intervention group
Intervention type: DRUG
Intervention: Sitagliptin/metformin
Description: Sitagliptin/metformin 50/500 mg, 50/850 mg, or 50/1000 mg tablet administered twice daily with meals.
Study NCT02057666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tasquinimod
Description: A patient initially received a 0.25 mg/day dose which was then titrated through 0.5 mg/day (from Day 15) to a maximum of 1 mg/day (from Day 29). If tolerability issues arose at 0.5 or 1 mg/day, patients had their dose reduced to 0.25 or 0.5 mg/day, respectively.
Study NCT02057666 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules were identical to tasquinimod capsules in appearance and excipients but excluded the active compound (tasquinimod).
Study NCT01749735 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Direct Current Stimulation
Description: Sham transcranial direct current stimulation will be used while the participant focuses on repetitive tasks using the Armeo device that incorporate multidirectional reaching, grasp and release action of the hand of the affected arm. Intervention: 40 minute training sessions, 5 days a week for 2 weeks.
Study NCT01749735 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Armeo training
Description: Upper extremity training with the use of a weight support device and virtual reality.
Study NCT01749735 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Armeo training
Description: Upper extremity training with the use of a weight support device and virtual reality.
Study NCT01221051 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: active management of the third stage of labor
Description: early cord clamping, administration of oxytocin 10 IU, controlled cord traction, uterine massage after placenta expulsion
Study NCT01221051 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: expectant management of the third stage of labor
Description: early cord clamping, administer saline solution 2 mL i.v,wait for signs of placenta detachment, encourage the woman to push ot placenta by her own effort, uterine massage after placenta expulsion
Study NCT01645280 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + methotrexate (MTX) (Group 1)
Description: Placebo: form = solution for injection, route = subcutaneous use, at Weeks 0, 4, then every 8 weeks (Weeks 12, 20, and 28) + MTX (pre-study dose)
Study NCT01645280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab + MTX (Group 2)
Description: Ustekinumab: type = exact number, unit = mg, number = 90, form = solution for injection, route = subcutaneous use, at Weeks 0, 4, then every 8 weeks (Weeks 12, 20, and 28) + MTX (pre-study dose)
Study NCT01645280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab + MTX (Group 3)
Description: Ustekinumab: type = exact number, unit = mg, number = 90, form = solution for injection, route = subcutaneous use, at Weeks 0, 4, then every 12 weeks (Weeks 16 and 28) + MTX (pre-study dose)
Study NCT02330809 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Timing of daily extra water intake
Description: Intervention-A: Timing of daily extra water intake specified Intervention-B: at any time during 24 hour period
Study NCT00579436 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: omega-3 fatty acid
Description: 4g of omega-3 fatty acid daily by mouth for 12 weeks.
Study NCT00579436 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 4 inert capsules daily by mouth for 12 weeks.
Study NCT04679545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBD
Description: A water-soluble sublingual tablet containing 20 mg of CBD.
Study NCT04679545 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: An inactive compound.
Study NCT02312882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Description: Tofacitinib 5 mg tablet taken by mouth twice a day.
Study NCT01255787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Description: Vortioxetine tablets
Study NCT00018616 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: MEMS caps
Study NCT01645280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 1959 + MTX (Group 4)
Description: CNTO 1959: type = exact number, unit = mg, number = 200, form = powder for solution for injection, route = subcutaneous use, at Weeks 0, 4, then every 8 weeks (Weeks 12, 20, and 28) + MTX (pre-study dose)
Study NCT01645280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 1959 + MTX (Group 5)
Description: CNTO 1959: type = exact number, unit = mg, number = 50, form = powder for solution for injection, route = subcutaneous use, at Weeks 0, 4, then every 8 weeks (Weeks 12, 20, and 28)+ MTX (pre-study dose)
Study NCT01930409 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Support and Coaching
Description: The participants will receive up to 5 telephone calls of 30-45 minutes each after hospital discharge to provide support and education for the transition from acute to community care. The first call will be made within 48-72 hours of hospital discharge and will have the following elements:~* Health Status~* Medication Management~* Activity/Exercise Prescription and Goal-Setting~* Falls Prevention~* Clarification of Appointments~* Coordination of Post-Discharge Home Services~* What To Do If a Problem Arises
Study NCT01930409 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education Only
Description: An educational toolkit will be provided, with materials to self manage at home after hospital discharge following a fall related hip fracture
Study NCT01930409 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education Only
Description: An educational toolkit will be provided, with materials to self manage at home after hospital discharge following a fall related hip fracture
Study NCT01512524 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: MRI scan and endocrinology analysis
Description: Endocrinology analysis including statique and dynamic exams, neuropsychologic evaluations and IRM scan.
Study NCT02157272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: Rivaroxaban
Description: The investigated drug is Rivaroxaban 20mg, a film coated tablet, which is a highly selective direct factor Xa inhibitor. It should be administered orally, every day at any time (always the same), with food. The treatment should be performed for all the treatment period.
Study NCT02642471 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: no systematic pelvic lymphadenectomy
Description: systematic pelvic lymphadenectomy is omitted in surgical treatment
Study NCT03500094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Migalastat HCl 150 mg
Description: migalastat HCl 150 mg capsule
Study NCT04428645 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DailyDose Decision Support
Description: DailyDose provides on-demand, real-time dosing recommendations for insulin meal boluses and basal insulin doses as well as the option to receive recommendations for meals and exercise. DailyDose is an information system comprised of (1) a smart phone app that both collects continuous glucose measurement (CGM) data, insulin data, and fitness data and presents suggestions back to the user, (2) a cloud based information system that stores the raw data and relays suggestions to the user, (3) a glucoregulatory model, automatically personalized for each user, that resides on a cloud server and is fit with the user's individual glucose data, and (4) an adaptive agent that provides insulin dosing options and suggestions as well as meal and exercise recommendations to the user based on the subject's own outcomes and simulations done on the glucoregulatory model.
Study NCT02372006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: afatinib
Study NCT03502733 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy
Study NCT03789110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is called an anti- PD-1 or a checkpoint inhibitor and is an antibody (a type of human protein) designed to allow the body's own immune system to destroy tumors
Study NCT03789110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab is called an anti-CTLA-4 and is a type of antibody that works to prevent the body's immune system from stopping to fight a specific cancer
Study NCT04225364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: camrelizumab
Description: Participants will receive camrelizumab, 200mg, intravenously over 30 - 60 minutes, day 1 of every 3 weeks for 6 weeks. Discontinuation will be considered due to toxicity, withdrawal of consent, or end of study. Every 3-week treatment period was considered to be a cycle.
Study NCT04225364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel for injection (albumin-bound)
Description: Paclitaxel for injection (albumin-bound): 260mg/m2(in total), ivgtt d1, d8, q3w，for 2 cycle
Study NCT04225364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75mg/m2(in total), ivgtt d1-d3, q3w, for 2 cycles
Study NCT03097198 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plum-blossom Needle
Description: * acupoint selection: Zhengguang 1, Zhengguang 2, GB20, GV14, LI4.~* plum-blossom needle manipulation methods: After the skin has been wiped with 75 % alcohol, plum-blossom needles will be tapped perpendicularly on the skin at the selected acupoints with wrist force and then lifted immediately. Each point will be tapped repeatedly for 20 to 50 times and both sides of cervical vertebra and temporal region, Suprao-infraorbital margin will be tapped repeatedly. Acupuncturists should tap the points gently to make patients feel only a little pain and stop when the skin gets flushed but is not bleeding.
Study NCT03097198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tropicamide Eye Drops
Description: Instill one drop in both eyes every night before bed.
Study NCT03416673 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peCTG+CAF
Description: A connective tissue graft will be reshaped to have extensions mimicking the papillae to augment the inter-dental papillae recessed
Study NCT03502733 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT03502733 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan
Study NCT03416673 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CTG+CAF
Description: A connective tissue graft harvested from the palate will be sutured to the gingival recession site and covered with a coronally advanced flap
Study NCT03502733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib
Description: Given IV
Study NCT04917991 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Extra Virgin Olive Oil-enriched chocolate spread
Description: the intervention consists in the administration of 100g Extra Virgin Olive Oil-enriched chocolate spread each day for 14 days.
Study NCT04917991 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Palm Oil-enriched chocolate spread
Description: the intervention consists in the administration of 100g Palm Oil-enriched chocolate spread each day for 14 days.
Study NCT03843294 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TAA-T cells
Description: The patient will receive two TAA-T cell infusions given 2 weeks apart. TAA-T cell dose: 2 x 107 cells/m2.per infusion.
Study NCT03843294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab: For patients \<18 years, 3 mg/kg/dose (maximum 240mg/dose) every 2 weeks. For adult patients ≥18 years, a dose of 240mg every 2 weeks or 480mg every 4 weeks
Study NCT03502733 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO
Study NCT03028792 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Modification Program
Description: Each trial begins with a fixation cross at the center of the computer screen for 500 ms. The cross is then replaced by a face pair presented in the center of the screen. The face pair disappears and a probe (letter E or F) appears immediately in the location of one of the two previous stimuli. Youth will be instructed to decide whether the letter is an E or an F and press the corresponding mouse button. This paradigm has been modified to facilitate an attention bias away from threat material. In this case, the probe always replaces the neutral stimuli. Thus, although there will be no specific instruction to direct attention away from the threat stimuli, on all trials, the position of the neutral stimulus will indicate the position of the probe.